AlphaVax Human Vaccines, Inc.

Established to commercialize the proprietary AlphaVax vector system, An innovative vaccine delivery technology. AlphaVax, Inc.,based in Durham, North Carolina, has been established to commercialize the proprietary AlphaVax vector system, an innovative vaccine delivery technology. The AlphaVax technology constitutes a major advance in vector technology and presents the opportunity to immunize against diseases notcurrently preventable with vaccines and to substantially improve existing vaccines. Immediate applications of the vectors include preventative and therapeutic human vaccines for infectious diseases and cancer and the production of vaccine intermediates and therapeutic proteins. AlphaVax is focusing on an aggressive development plan for a vaccine to treat human immunodeficiency virus (HIV) due to the critical need for new preventative measures and accelerated development timelines. AlphaVax products will target the human vaccine market.

Activity:

Product / Technology type(s) covered:

- Drug delivery
- Proteins
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: